Journal Article Summary
The article investigates the risk of venous thrombosis, a serious condition where blood clots form in the veins, among women using non-oral hormonal contraception, such as transdermal patches and vaginal rings. This topic is important because previous studies have primarily focused on oral contraceptives, leaving a gap in understanding the risks associated with non-oral methods. By examining a large population of Danish women, the study aims to provide clearer insights into how different types of hormonal contraception may affect the likelihood of developing venous thrombosis.
The researchers conducted a historical cohort study using data from four national registries in Denmark, tracking 1,626,158 non-pregnant women aged 15-49 from 2001 to 2010. They found that among the women studied, those using transdermal patches had a significantly higher risk of venous thrombosis, with a relative risk of 7.9 compared to non-users, while vaginal ring users had a relative risk of 6.5. The study also noted a slight increase in risk for women using subcutaneous implants but found no increased risk for those using the levonorgestrel intrauterine system.
Despite its strengths, such as a large sample size and reliable data collection methods, the study has limitations. It could not account for factors like family history or body mass index, which are known risk factors for venous thrombosis. Patients should discuss these findings with their healthcare providers, especially if they are considering or currently using non-oral hormonal contraception, to understand their individual risks and explore safer alternatives if necessary.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Lidegaard Øjvind, Nielsen Lars Hougaard, Skovlund Charlotte Wessel, Løkkegaard Ellen. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. The BMJ 2012. DOI: 10.1136/bmj.e2990. PMID: 22577198. PMCID: PMC3349780.
Featured Pill Pals Product
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive --- Perrigo
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive --- Perrigo is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. No prescription required for eligible over-the-counter purchases.
